

LACRYSTIM[®]

TREATMENT OF
DRY EYE



I.P.L. System

LACRYSTIM®

Dry eye is a particularly common disease that affects the **health and well-being** of millions of people worldwide. **Meibomian gland dysfunction** (MGD) is the leading cause of dry eye syndrome, known as evaporative dry eye, because it causes excessive tear evaporation. Dry eye disease can also be caused by a poor tear production of the lacrimal glands.


The **I.P.L. LacryStim® system** (Intense Pulsed Light) helps stimulate and reactivate the Meibomian glands and lacrimal glands in order to treat dry eye. Intense Pulsed Light technology is one of a series of innovative technologies **acknowledged in the TFOS-DEWS II Report**.

TREATS THE CAUSES OF DRY EYE OPTIMISES LONG-TERMS RESULTS.

■ MECHANISMS OF ACTION

Several studies detail the mechanisms of action of I.P.L. systems:

- **Neurostimulation of the parasympathetic nerve pathways [1,2].**
Tear production is stimulated by the nervous system, via the parasympathetic nerve [3], which is linked to both the lacrimal gland [3,4] and the meibomian glands [3,5].
- **Faster Meibomian gland and lacrimal gland metabolism [1,2,3,4,5,12,13].**
- **Increased meibum expression due to heat [6].**
- **Small vessel coagulation: acts against inflammation of the skin** (rosacea) and **eyelids** (blepharitis) [7,8,9].
- **Reduces Demodex mites.**



■ CLINICAL RESULTS


The expected results of I.P.L. treatment may include [6]:

- Improved **tear film quality**.
- Patient-reported **improvement in the following symptoms:** dryness, sensation of foreign body in the eye, itching, burning, eye fatigue, blurred vision, sensitivity to light, watery eyes, impaired secretion, pain.
- **Additional effects of I.P.L. treatment may be observed:**
 - Pain relief
 - Anti-inflammatory action (blepharitis, rosacea)
 - Reduction in inflammatory markers (cytokines) in the tears [10]
 - On infections (Demodex).

I.P.L. System


■ LIGHT SPECTRUM

- An **I.P.L.** device is a generator of **polychromatic intense pulsed light**.
- The LacryStim light spectrum extends **from 610 nm to 1200 nm**.
- LacryStim uses a **610 nm filter** that blocks UVA, UVB and UVC rays.
- Thanks to **this 610 nm filter**:
 - The **melanin** in the skin **absorbs less light** [11]
 - **Phototypes 1 to 5** (from the Fitzpatrick scale) can be treated.



■ SETTINGS AND PULSE SEQUENCE

- **The total energy** is between 8 and 12 J/cm² and is delivered in a **sequence of pulses**.
- The **time between each pulse respects the thermal relaxation time (TRT) of the skin**, thus limiting:
 - The increase in tissue temperature
 - Thermal damage to the skin
 - Inflammatory reactions.



➤➤ A SAFE AND EFFECTIVE TREATMENT FOR SKIN TYPES 1 TO 5




LACRYSTIM[®]
610 - 1200 nm

■ COMFORT AND EASE OF USE

- **Integrated water cooling:**
 - **Does not burn** the skin.
 - Applies a **thin layer of gel** during treatment.
 - **Long-lasting** flash lamp.
 - Delivers the **same energy level** from first to last shot.
- A single handpiece, no additional kit required.



■ SIMPLE AND FAST TREATMENT






THE BENEFITS OF

DIAGNOSIS
LACRYDIAG®
Eye surface analyser



TREATMENT
LACRYSTIM®
I.P.L. System



ADDED VALUE FOR YOUR CLINICAL PRACTICE

- Extend your clinical offering from diagnosis to treatment.
- Diagnose and treat the cause of dry eye earlier.
- Offer effective and lasting I.P.L. treatment.
- Optimise post-surgical results by diagnosing and treating before surgery (refractive, cataract).
- Improve the compliance of patients under topical treatment for glaucoma.



IMPROVED COMFORT FOR YOUR PATIENTS

- Perform a complete, fast contactless examination.
- Offer your patients painless and effective I.P.L. treatment (< 5 min).
- Provide evidence of diagnosis and I.P.L. treatment results.
- Improve patient care.
- Ensure patient satisfaction from the 1st I.P.L. treatment.

LACRYSTIM®

TECHNICAL SPECIFICATIONS

LACRYSTIM®

Technology	I.P.L. (Intense Pulsed Light)
Wavelength	610 – 1200 nm
Energy	1 to 14 J/cm ²
Dimensions	580 (H) x 275 (W) x 280 (D) mm
Weight	25 kg
Filter	610 nm, anti UVA, UVB and UVC filter
Cooling system	Water
	Replace water every 7000 shots
Flash lamp	Xenon lamp
Power supply	230 VAC or 110 VAC
Temperature for use	+5°C to +35°C
Treatment duration	3 to 4 sessions
Accessories	Operator safety glasses, patient eyeshields
CE marking	Class IIb medical device

The company reserves the right to modify the technical specifications without prior warning.
© 2020. Quantel Medical, LacryStim® is a registered trademark of Quantel Medical. All rights reserved.

BIBLIOGRAPHY

1. Parasympathetic Innervation of the Meibomian Glands in Rats - Mark, S. LeDoux, Qihong Zhou, R. Bryan Murphy, Melissa, L. Greene y Patrick Ryan - *Investigative Ophthalmology & Visual Science*, octubre de 2001, Vol. 42, No. 11
2. Neurotransmitter Influence on Human Meibomian Gland Epithelial Cells. - Wendy R. Kam y David A. Sullivan - *Investigative Ophthalmology & Visual Science*, noviembre de 2011, vol. 52, No. 12
3. TFOS DEWS II - Rapport Physiopathologie, Anthony J. Bron, FRCOph, FMedSci, Cintia S. de Paiva, MD, PhD1, Sunil K. Chauhan, DVM, PhD1, Stefano Bonini, MD, Eric E. Gabison, MD, Sandeep Jain, MD, Erich Knop, MD, PhD, Maria Markoulli, PhD, MOptom, Yoko Ogawa, MD, Víctor Pérez, MD, Yuichi Uchino, MD, PhD, Norihiko Yokoi, MD, PhD, Driss Zoukhri, PhD, David A. Sullivan, PhD, *The Ocular Surface*, 2017, pp. 441-515
4. Vasoactive Intestinal Polypeptide and the Innervation of the Human Lacrimal Gland, Patrick A. Sibony, MD; Benjamin Walcott, PhD; Cissy McKeon, Frederick A. Jakobiec, MD, *Arch Ophthalmol.* 1988;106(8), pp. 1085-1088
5. The neurobiology of the meibomian glands, Cox SM, Nichols JJ, *Ocular Surface*, julio de 2014
6. Arita R. et al. Multicenter Study of Intense Pulsed Light Therapy for Patients With Refractory Meibomian Gland Dysfunction - Reiko Arita, MD, PhD, Takanori Mizoguchi, MD, Shima Fukuoka, MD, and Naoyuki Morishige, MD, PhD - *Cornea*, volumen 37, número 12, diciembre de 2018
7. Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition, Yu Ri Woo, Ji Hong Lim, Dae Ho Cho and Hyun Jeong Park, *International Journal of Molecular Sciences*, septiembre de 2016
8. Rosacea: Epidemiology, pathogenesis, and treatment, Barbara M. Rainer, Sewon Kang, and Anna L. Chien, *DERMATO-ENDOCRINOLOGY* 2018, VOL. 9, NO. 1, e1361574 (10 páginas)
9. Update on the management of rosacea, Allison P Weinkle, Vladyslava Doktor, Jason Emer, *Clinical, Cosmetic and Investigational Dermatology*, abril de 2015
10. Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction - RUIXING LIU, BEI RONG, PING TU, YUN TANG, WENJING SONG, ROLANDO TOYOS, MELISSA TOYOS Y XIAOMING YAN - *Am J Ophthalmol.* 2017 en AJO.com.
11. Theory of lasers and lamps - S. Mordon, T. Michaud - *Annales de dermatologie* (2009) 136, suplemento 6, S3066s310 - www.sciencedirect.com
12. Effect of inflammation on lacrimal gland function - Driss Zoukhri - *Experimental Eye Research*, 2006 May ; 82(5): 885-898.
13. Aqueous deficiency is a contributor to evaporation-related dry eye disease - Charles W. McMonnies - *Eye and Vision* (2020) 7:6

LacryStim® I.P.L. is a class IIb medical device designed by CSB for QUANTEL MEDICAL and compliance assessed by IMQ CE 0051.

www.quantel-medical.com



PREMED PHARMA KFT.
CÍM 2040 Budaörs, Gyár u. 2.
TELEFON 06 23 889 700
FAX 06 23 889 710
E-MAIL info@premedpharma.hu
WEB www.premedpharma.hu

Headquarters
Quantel Medical
11, rue du Bois Joli - CS40015
63808 Cournon d'Auvergne - FRANCE
Tel: +33 (0)4 73 745 745
Email: contact@quantel-medical.fr

North America
Quantel Medical USA
2313 Ridge Road Suite 105A
Rockwall, TX 75087 - USA
Tel: +1 888 660 6726
Email: info@quantelmedical.com

Poland
Quantel Medical
ul. Raławicka 93
02-634 Warszawa - POLAND
Tel: +48 22 5210111
Email : info@quantel-medical.pl

BY LUMIBIRD

ISO 9001 : 2015 - ISO 13485 : 2016

Representative Offices
Thailand, Chiang Mai
Brazil, Rio De Janeiro

